Skip to main
MBOT
MBOT logo

Microbot Medical (MBOT) Stock Forecast & Price Target

Microbot Medical (MBOT) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Microbot Medical Inc. is positioned for growth within a total addressable market of 2.5 million annual peripheral endovascular procedures in the U.S., highlighting significant potential for market expansion. The LIBERTY Endovascular Robotic System offers enhanced procedure efficiency, cost reduction, and improved quality of care, making it an attractive option for both patients and healthcare providers. Additionally, a notable achievement is the mean 92% relative reduction in radiation exposure for operators compared to traditional methods, underscoring the system's advanced safety features and technological superiority.

Bears say

Microbot Medical Inc faces significant risks that may hinder its stock performance, primarily due to slower than expected commercial uptake of its LIBERTY Endovascular Robotic System. This risk is compounded by factors such as the overall market size, penetration rate, and competitive pressures within the medical device industry. Additionally, potential dilution risk poses a concern for investors, which could further negatively impact stock valuation.

Microbot Medical (MBOT) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Microbot Medical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Microbot Medical (MBOT) Forecast

Analysts have given Microbot Medical (MBOT) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Microbot Medical (MBOT) has a Strong Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Microbot Medical (MBOT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.